Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in the development of drug engaged in the research, development and commercialization of pharmaceutical products. The company's products are used for the treatment of metabolic diseases, including diabetes, obesity and overweight, and MASH; and other major central nervous system diseases. The company was incorporated in 2014 and is based in Shanghai, China.
Frequently asked questions
What sector does Guangzhou Innogen Pharm Grp Co (2591) operate in?
Guangzhou Innogen Pharm Grp Co belongs to the Other sector and operates in the Biotechnology industry.
What is Guangzhou Innogen Pharm Grp Co (2591) current stock price?
As of the latest data, Guangzhou Innogen Pharm Grp Co stock price is HK$3.19, with a previous close of HK$3.29. Guangzhou Innogen Pharm Grp Co lost -HK$0.10 in the last trading session, representing a -3.04% loss.
What is Guangzhou Innogen Pharm Grp Co (2591) current market capitalization?
Guangzhou Innogen Pharm Grp Co market cap is approximately 1.34 billion.
What is Guangzhou Innogen Pharm Grp Co (2591) EBITDA?
Guangzhou Innogen Pharm Grp Co EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -109.26 million.
Does Guangzhou Innogen Pharm Grp Co (2591) pay dividends?
No. Guangzhou Innogen Pharm Grp Co does not pay a dividend.
What is Guangzhou Innogen Pharm Grp Co (2591) beta (volatility) score?
Guangzhou Innogen Pharm Grp Co has a beta of -0.224, indicating lower volatility than the overall market.